PHARMAC is pleased to announce the approval of an agreement with Novartis New Zealand Ltd involving the listing of nine new products and amendments to the listing of seven other products.
PHARMAC is seeking feedback on a proposal to list insulin aspart (NovoRapid FlexPen) in Section B and Part II of Section H of the Pharmaceutical Schedule from 1 December 2014. Closes: Monday, 20 October 2014.
Proposal relating to the listing of docusate sodium with sennosides tablet 50 mg with total sennosides 8 mg and prednisolone sodium phosphate oral liquid 5 mg per ml
PHARMAC is seeking feedback on a proposal relating to provisional agreements for supply of the oral tablet docusate sodium with sennosides (“Laxsol”) and for prednisolone sodium phosphate oral liquid (“Redipred”). Closes: Friday, 17 October 2014.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2013/14 Invitation to Tender, dated 07 November 2013.
The first funded pharmaceutical treatment for Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neurone disease, will become available from 1 October 2013.
Addition of Coloplast range of wound care products to Universal Specialities Limited trading as USL Medical (USL) listing agreement
PHARMAC advises that as of 1 October 2014, a range of Coloplast wound care products already in use in the DHBs, will be added to the USL Listing Agreement and listed in Section H, Part III, (‘Optional Pharmaceuticals’) of the Pharmaceutical Schedule.
PHARMAC is pleased to announce the approval for the listing and supply of levonorgestrel 2 x 75 mg rods (Jadelle).
Proposal to list a range of interventional cardiology products supplied by Bio-Excel (Australia) Pty Ltd
PHARMAC is seeking feedback on a proposal to list a range of interventional cardiology products supplied by Bio-Excel (Australia) Pty Ltd (“Bio-Excel”) in Part III of Section H of the Pharmaceutical Schedule from 1 November 2014. Closes: Monday, 13 October 2014.
PHARMAC is pleased to announce decisions relating to various contrast media that will take effect from 1 October 2014 through an agreement with Regional Health Limited.
PHARMAC is seeking feedback on a proposal to list ceftaroline fosamil in Part II of Section H of the Pharmaceutical Schedule. Closes: Friday, 19 September 2014.
The smaller particles delivered by the newly-funded Qvar inhalers mean patients changing to this presentation will usually require lower doses.
PHARMAC requests tenders for the supply of infliximab to DHB hospitals in New Zealand. Closes: 5 pm Tuesday, 30 September 2014.
PHARMAC is pleased to announce decisions to remove or amend the funding restrictions for a number of pharmaceuticals.
PHARMAC is seeking feedback on a proposal to fund a contraceptive implant in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 October 2014.
PHARMAC is pleased to announce the approval of an agreement with Jackson Allison Medical & Surgical Limited (“Jackson Allison”) for the supply of wound care products
Genetic markers will be used to target a new funded oral treatment for hepatitis C patients from 1 September.
Amendment to the terms of listing of disposable laparoscopic supplies on the Pharmaceutical Schedule
PHARMAC notification to amend agreement with Applied Medical New Zealand Limited for disposable laparoscopic devices.
Up to 400 patients a year are likely to live longer as a result of PHARMAC funding two new medicines.
New Zealanders’ use of generic medicines is likely to grow further following the just-completed 2013/14 PHARMAC tender.
PHARMAC is interested in considering proposals from suppliers of medicines for rare disorders for the funding and listing of their products in the Pharmaceutical Schedule. Closes: 5 pm, 25 September 2014.